A Phase I/II study of Neratinib in pediatric patients with relapsed or refractory solid tumors or hematologic malignancies

Sponsor: Puma

Protocol: POE16-01

Principal investigator: Tanya Trippett, MD

Site: Memorial Sloan Kettering Cancer Center

Estimated accrual years: 1.0 (Phase I); 1.5 (Phase II)